Table 1.
Diagnostic sensitivity of TBLC for each disease.
| MDD diagnosis | Sensitivity without C/R (n = 431) | Sensitivity with C/R (n = 213) | ||
|---|---|---|---|---|
| n (%) | P value | n (%) | P value | |
| IIP | 95/146 (65.1%) | 50/62 (80.7%) | ||
| IPF | 77/106 (72.6%) | 43/50 (86.0%) | ||
| Idiopathic NSIP | 0/6 (0.0%) | < 0.001* | 0/2 (0.0%) | 0.027* |
| COP | 7/12 (58.3%) | 0.323* | 1/1 (100%) | 1.000* |
| SR-ILD | 7/17 (41.2%) | 0.022* | 4/7 (57.1%) | 0.095* |
| HP | 50/88 (56.8%) | 0.215** | 42/52 (80.8%) | 1.000** |
| Fibrotic HP | 34/67 (50.8%) | 0.009* | 30/37 (81.1%) | 0.567* |
| Non-fibrotic HP | 16/21 (76.2%) | 1.000* | 12/15 (80.0%) | 0.685* |
| Iatrogenic | 9/14 (64.3%) | 1.000** | 2/5 (40.0%) | 0.070** |
| Drug induced ILD | 9/12 (75.0%) | 1.000* | 2/4 (50.0%) | 0.125* |
| Radiation pneumonitis | 0/2 (0.0%) | 0.081* | 0/1 (0.0%) | 0.157* |
| CTD-ILD | 24/54 (44.4%) | 0.010** | 29/33 (87.9%) | 0.566** |
| RA | 10/21 (47.6%) | 0.038* | 11/12 (91.7%) | 1.000* |
| Sjogren syndrome | 2/8 (25.0%) | 0.010* | 4/5 (80.0%) | 0.559* |
| SSc | 2/8 (25.0%) | 0.010* | 5/6 (83.3%) | 1.000* |
| PM/DM | 4/6 (66.7%) | 0.668* | 5/5 (100%) | 1.000* |
| AAV | 3/8 (37.5%) | 0.050* | 2/3 (66.7%) | 0.394* |
| Other disease | 39/57 (68.4%) | 0.742** | 15/17 (88.2%) | 0.722** |
| Sarcoidosis | 8/11 (72.7%) | 1.000* | 3/4 (75.0%) | 0.484* |
| Infection | 6/10 (60.0%) | 0.467* | 0/1 (0.0%) | 0.157* |
| Pneumoconiosis | 2/4 (50.0%) | 0.315* | 1/1 (100%) | 1.000* |
| Unclassifiable ILD | 14/72 (19.4%) | < 0.001** | 9/35(20.5%) | < 0.001** |
Significant values are in bold.
AAV, anti-neutrophil cytoplasmic antibody associated vasculitis; COP, cryptogenic organizing pneumonia; C/R, clinical/radiological information; CTD, connective tissue disease; HP, hypersensitivity pneumonitis; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; NSIP, non-specific interstitial pneumonia; PM/DM, polymyiositis/dermatomyositis; RA, rheumatoid arthritis; SR-ILD, smoking related interstitial lung disease; SSc, systemic sclerosis.
* Compared with IPF.
** Compared with IIPs.